Study on the Efficacy and Mechanism of METTL3 Peptide Inhibitors in Enhancing Anti-tumor Immune Response by Reshaping the Tumor Microenvironment

Launched by XIJING HOSPITAL · Jan 7, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment approach for patients with bladder, prostate, and kidney cancers. The study is focused on a substance called METTL3, which researchers believe could help improve how the body’s immune system fights tumors. Specifically, they want to see if METTL3 can be used as a reliable way to predict how well patients will respond to immune therapy, which is a type of treatment that helps the immune system attack cancer.

To participate in this study, patients must be diagnosed with a urinary system tumor and meet certain medical guidelines, such as having undergone surgical treatment. They should be between the ages of 18 and 75 and be able to understand and communicate about the study. If eligible, participants will provide tissue samples during surgery, and their responses to the treatment will be observed. This study is currently not recruiting participants, but it aims to gather important information that could help improve cancer treatments in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients diagnosed with urinary system tumors through pathological examination;
• • 2. Meet specific clinical stages and surgical treatment standards;
• • 3. Intraoperative tissue resection meets the sample testing standards;
• • 4. The patient is willing to participate in the study and sign an informed consent form.
• Exclusion Criteria:
• • 1. Not meeting the specific clinical stage and not receiving surgical treatment;
• • 2. Abnormal mental behavior;
• • 3. Intellectual disability;
• • 4. Age under 18 years old or over 75 years old;
• • 5. Low understanding and communication skills.